Date:2/17/2009

r dependence on a small number of customers, contract manufacturers and single source suppliers of raw materials, (x) changes in third-party reimbursement policies regarding our products could adversely affect sales of our products, (xi) changes in government regulation affecting our diagnostic products could harm our sales and increase our development costs, (xii) the risk that our intellectual property may be infringed by third parties or invalidated, and (xiii) our involvement in patent and other intellectual property and commercial litigation could be expensive, could divert management's attention, and could interfere with our ability to develop and distribute products. The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

(1) In this press release, all per share amounts are calculated on a fully diluted basis, and all results are presented in US GAAP. Some totals may not foot due to rounding.

    Contact:

    Michael Watts
    Vice president, investor relations and
    corporate communications
    858-410-8673



                             Gen-Probe Incorporated
                          Consolidated Balance Sheets
                 (In thousands, except share and per share data)


                                                   December 31,  December 31,
                                                       2008         2007
    Assets
    Curren
'/>"/>
SOURCE  Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Related medicine news :

1. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
2. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
3. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
4. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
5. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
8. Gen-Probe to Webcast Two Upcoming Investor Presentations
9. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
10. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
11. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference